Posizolid

Drug Profile

Posizolid

Alternative Names: AZD 2563; AZD-5847

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Institute of Allergy and Infectious Diseases
  • Class Antibacterials; Antituberculars; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gram-positive infections; Tuberculosis

Most Recent Events

  • 10 Feb 2016 Discontinued - Phase-I for Tuberculosis in USA (PO) prior to February 2016
  • 10 Feb 2016 Discontinued - Phase-II for Tuberculosis (Treatment-naive) in South Africa (PO) prior to February 2016 (AstraZeneca's pipeline, February 2016)
  • 13 Oct 2015 No development reported - Phase-I for Tuberculosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top